全文获取类型
收费全文 | 29995篇 |
免费 | 2166篇 |
国内免费 | 130篇 |
专业分类
耳鼻咽喉 | 428篇 |
儿科学 | 639篇 |
妇产科学 | 1084篇 |
基础医学 | 3824篇 |
口腔科学 | 829篇 |
临床医学 | 3140篇 |
内科学 | 6173篇 |
皮肤病学 | 477篇 |
神经病学 | 2826篇 |
特种医学 | 961篇 |
外科学 | 4138篇 |
综合类 | 519篇 |
一般理论 | 18篇 |
预防医学 | 2159篇 |
眼科学 | 688篇 |
药学 | 2099篇 |
1篇 | |
中国医学 | 135篇 |
肿瘤学 | 2153篇 |
出版年
2023年 | 139篇 |
2022年 | 213篇 |
2021年 | 625篇 |
2020年 | 352篇 |
2019年 | 534篇 |
2018年 | 700篇 |
2017年 | 478篇 |
2016年 | 517篇 |
2015年 | 678篇 |
2014年 | 915篇 |
2013年 | 1398篇 |
2012年 | 1946篇 |
2011年 | 2098篇 |
2010年 | 1287篇 |
2009年 | 1138篇 |
2008年 | 1808篇 |
2007年 | 1840篇 |
2006年 | 1851篇 |
2005年 | 1770篇 |
2004年 | 1683篇 |
2003年 | 1600篇 |
2002年 | 1560篇 |
2001年 | 714篇 |
2000年 | 633篇 |
1999年 | 520篇 |
1998年 | 321篇 |
1997年 | 297篇 |
1996年 | 286篇 |
1995年 | 240篇 |
1994年 | 205篇 |
1993年 | 161篇 |
1992年 | 290篇 |
1991年 | 258篇 |
1990年 | 215篇 |
1989年 | 186篇 |
1988年 | 196篇 |
1987年 | 159篇 |
1986年 | 160篇 |
1985年 | 156篇 |
1984年 | 170篇 |
1983年 | 168篇 |
1982年 | 186篇 |
1981年 | 163篇 |
1980年 | 171篇 |
1979年 | 114篇 |
1978年 | 138篇 |
1977年 | 113篇 |
1976年 | 116篇 |
1974年 | 88篇 |
1973年 | 83篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
2.
3.
4.
5.
6.
Tien‐Yao Tsai Iat‐Lon Leong Ka‐Shun Cheng Lian‐Ru Shiao Tzu‐Hui Su Kar‐Lok Wong Paul Chan Yuk‐Man Leung 《Fundamental & clinical pharmacology》2019,33(1):52-62
A pathological feature in atherosclerosis is the dysfunction and death of vascular endothelial cells (EC). Oxidized low‐density lipoprotein (LDL), known to accumulate in the atherosclerotic arterial walls, impairs endothelium‐dependent relaxation and causes EC apoptosis. A major bioactive ingredient of the oxidized LDL is lysophosphatidylcholine (LPC), which at higher concentrations causes apoptosis and necrosis in various EC. There is hitherto no report on LPC‐induced cytotoxicity in brain EC. In this work, we found that LPC caused cytosolic Ca2+ overload, mitochondrial membrane potential decrease, p38 activation, caspase 3 activation and eventually apoptotic death in mouse cerebral bEND.3 EC. In contrast to reported reactive oxygen species (ROS) generation by LPC in other EC, LPC did not trigger ROS formation in bEND.3 cells. Pharmacological inhibition of p38 alleviated LPC‐inflicted cell death. We examined whether heparin could be cytoprotective: although it could not suppress LPC‐triggered Ca2+ signal, p38 activation and mitochondrial membrane potential drop, it did suppress LPC‐induced caspase 3 activation and alleviate LPC‐inflicted cytotoxicity. Our data suggest LPC apoptotic death mechanisms in bEND.3 might involve mitochondrial membrane potential decrease and p38 activation. Heparin is protective against LPC cytotoxicity and might intervene steps between mitochondrial membrane potential drop/p38 activation and caspase 3 activation. 相似文献
7.
8.
Multidisciplinary predialysis education and team care (MDC) may slow the decline in renal function in patients with chronic kidney disease (CKD). However, associations between unexpected return during MDC and progression of renal dysfunction have not been characterized in patients with CKD. Our study aimed to determine the association between exacerbation of renal dysfunction and the frequency of unexpected return during follow-up.A total of 437 patients with CKD receiving multidisciplinary care between January 2009 and June 2013 at the Shin-Kong Wu Ho-Su Memorial Hospital were included in this retrospective observational cohort study, and multiple imputations were performed for missing data. The predictor was the frequency of unexpected return for follow-up during the first year after entering MDC. Main outcome was monthly declines in estimated glomerular filtration rates (eGFR). Moreover, the demographic data, comorbidities, history of medication, and routine laboratory data for patients with CKD were collected.Among all patients, 59.7% were male, the mean age at initiation of MDC was 69.4 ± 13.2 years, and the duration of follow-up was 21.4 ± 3.3 months. The subjects were divided into 2 groups according to frequencies of follow-up (≤4 and > 4 visits) during the 1st year of MDC. The patients with CKD were regularly followed up every 3 months as a part of MDC in our hospital, and patients who returned for more than 4 follow-up visits were included in the unexpected return group. In crude regression analyses, unexpected return was significantly associated with higher monthly declines of eGFR (β = 0.092, 95% confidence interval, 0.014–0.170). This association remained after adjustments for multiple variables, and subgroup analyses of unexpected return showed that male gender, older age, CKD stage 1 to 3, hypertension, history of coronary artery disease, and use of renin–angiotensin system blockade were significantly associated with declines in renal function.In conclusion, unexpected return for follow-up during the 1st year of MDC was significantly associated with the deterioration of renal function. 相似文献
9.
Diabetes mellitus(DM) negatively affects the development and progression of chronic liver diseases(CLD) of various etiologies. Concurrent DM and CLD are also associated with worse clinical outcomes with respect to mortality, the occurrence of hepatic decompensation, and the development of hepatocellular carcinoma(HCC). Unfortunately, early diagnosis and optimal treatment of DM can be challenging, due to the lack of established clinical guidelines as well as the medical complexity of this patient population. We conducted an exploratory review of relevant literature to provide an up-to-date review for internists and hepatologists caring for this patient population. We reviewed the epidemiological and pathophysiological associations between DM and CLD, the impact of insulin resistance on the progression and manifestations of CLD, the pathogenesis of hepatogenic diabetes, as well as the practical challenges in diagnosis and monitoring of DM in this patient population. We also reviewed the latest clinical evidence on various pharmacological antihyperglycemic therapies with an emphasis on liver disease-related clinical outcomes. Finally, we proposed an algorithm for managing DM in patients with CLD and discussed the clinical and research questions that remain to be addressed. 相似文献